Stellar Biotechnologies Launches New Corporate Website
Complete the form below to unlock access to ALL audio articles.
Stellar Biotechnologies, Inc. has announced the launch of its new corporate website at www.stellarbiotech.com.
Stellar's new website features expanded content in a new format designed to provide customers and investors with the most comprehensive and current information about the Company and its world-leading technology in Keyhole Limpet Hemocyanin (KLH).
The website details Stellar's KLH products, breakthroughs in aquaculture science and strategic expansion of its own immunotherapy program targeting Clostridium difficile ("C. diff") infection.
It also includes a significantly enhanced Investor Relations section intended to streamline access to relevant corporate materials and broaden online exposure for the Company. The Investor Relations pages include up-to-the-minute data, news, corporate presentations, and direct access to historical financial filings.
Mark A. McPartland, Vice President of Corporate Development and Communications of Stellar Biotechnologies, said, "A primary objective for Stellar is presenting key information to stakeholders who are interested in the Company with the most timely and well-organized material. We believe our new website achieves this goal by accurately presenting Stellar's industry-leading KLH technology, products, scientific breakthroughs, expansion of our own immunotherapy program and environmentally sustainable advantage in a user-friendly platform."
Mr. McPartland continued, "A main focal point of the new website is to maximize Stellar's level of corporate transparency for the benefit of investors and we are confident that it succeeds in furthering this transparency. Additionally, the new website allows us to archive an extensive range of corporate materials and information that can be easily accessed by users at their convenience on any Internet-enabled device."
